한글목차

유도만능줄기세포 생산 시장은 2023-2028년 18억 4,179만 달러 규모에 달할 것으로 예상되며, 예측 기간 동안 연평균 11.66%의 CAGR을 기록할 것으로 전망됩니다.

본 조사 보고서는 유도만능줄기세포 생산 시장의 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인 및 저해요인, 과제, 약 25개 벤더를 포함한 벤더 분석 등을 정리하여 전해드립니다.

현재 시장 시나리오, 최신 동향 및 촉진요인, 전체 시장 환경에 대한 최신 분석을 제공합니다. 이 시장은 여러 만성 질환의 유병률 증가, 신약 개발 및 독성 스크리닝 응용 분야에서 iPS 세포의 채택 증가, 개인 맞춤형 의약품을 위한 iPS 세포에 대한 수요 증가에 의해 주도되고 있습니다.

이 보고서는 향후 몇 년 동안 유도만능줄기세포 생산 시장의 성장을 견인할 주요 요인 중 하나로 세포 초기화 기술의 진보를 꼽았습니다. 또한, 유도만능줄기세포은행 및 보관의 출현, 재생의료 분야에서의 유도만능줄기세포 적용 확대도 시장의 큰 수요를 견인할 것으로 보입니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 상황

• 시장 생태계

제3장 시장 규모 평가

• 시장 정의
• 시장 부문 분석
• 시장 규모 2023
• 시장 전망 2023-2028

제4장 시장 규모 실적

• 유도만능줄기세포 생산 세계 시장 2018-2022
• 최종사용자별 부문 분석 2018-2022
• 제품별 부문 분석 2018-2022
• 지역별 부문 분석 2018-2022
• 국가별 부문 분석 2018-2022

제5장 Five Forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 참여업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 상황

제6장 최종사용자별 시장 세분화

• 시장 부문
• 비교 : 최종사용자별
• 병원 : 시장 규모와 예측 2023-2028
• 조사기관 : 시장 규모와 예측 2023-2028
• 바이오테크놀러지 기업 : 시장 규모와 예측 2023-2028
• 기타 : 시장 규모와 예측 2023-2028
• 시장 기회 : 최종사용자별

제7장 제품별 시장 세분화

• 시장 부문
• 비교 : 제품별
• 소모품과 키트 : 시장 규모와 예측 2023-2028
• 기구 : 시장 규모와 예측 2023-2028
• 서비스 등 : 시장 규모와 예측 2023-2028
• 시장 기회 : 제품별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측 2023-2028
• 유럽 : 시장 규모와 예측 2023-2028
• 아시아 : 시장 규모와 예측 2023-2028
• 세계 기타 지역 : 시장 규모와 예측 2023-2028
• 미국 : 시장 규모와 예측 2023-2028
• 중국 : 시장 규모와 예측 2023-2028
• 영국 : 시장 규모와 예측 2023-2028
• 독일 : 시장 규모와 예측 2023-2028
• 캐나다 : 시장 규모와 예측 2023-2028
• 시장 기회 : 지역 상황별

제10장 촉진요인, 과제 및 동향

• 시장 성장 촉진요인
• 시장 과제
• 성장 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 상황

• 개요
• 벤더 상황
• 혼란 상황
• 업계 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Allele Biotechnology and Pharmaceuticals Inc.
• Applied Biological Materials Inc.
• Applied StemCell
• ATCC
• Axol Biosciences Ltd.
• Cynata Therapeutics Ltd.
• Evotec SE
• Fate Therapeutics Inc.
• FUJIFILM Corp.
• Hitachi Ltd.
• LIFE and BRAIN GmbH
• Lonza Group Ltd.
• Ncardia Services B.V.
• REPROCELL Inc.
• Takara Bio Inc.

제13장 부록

영문목차

The induced pluripotent stem cells production market is forecasted to grow by USD 1841.79 mn during 2023-2028, accelerating at a CAGR of 11.66% during the forecast period. The report on the induced pluripotent stem cells production market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of several chronic disorders, increasing adoption of ipscs in drug discovery and toxicity screening applications, and growing demand for ipscs for personalized medicines.

Technavio's induced pluripotent stem cells production market is segmented as below:

By End-user

• Hospitals
• Research institutes
• Biotechnology companies
• Others

By Product

• Consumable and kits
• Instrument
• Services and others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the advancements in cell reprogramming techniques as one of the prime reasons driving the induced pluripotent stem cells production market growth during the next few years. Also, emergence of ipsc banks and repositories and growing applications of ipscs in regenerative medicine will lead to sizable demand in the market.

The report on the induced pluripotent stem cells production market covers the following areas:

• Induced pluripotent stem cells production market sizing
• Induced pluripotent stem cells production market forecast
• Induced pluripotent stem cells production market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading induced pluripotent stem cells production market vendors that include Allele Biotechnology and Pharmaceuticals Inc., ALSTEM, Applied Biological Materials Inc., Applied StemCell, ATCC, Axol Biosciences Ltd., Becton Dickinson and Co., Bio Techne Corp., Board of Regents of the University of Wisconsin System, Creative Biolabs, Cyagen Biosciences, Cynata Therapeutics Ltd., Evotec SE, Fate Therapeutics Inc., FUJIFILM Corp., Hitachi Ltd., LIFE and BRAIN GmbH, Lonza Group Ltd., Ncardia Services B.V., REPROCELL Inc., Sartorius AG, STEMCELL Technologies Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc.. Also, the induced pluripotent stem cells production market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global induced pluripotent stem cells production market 2018 - 2022
• 4.2 End-user Segment Analysis 2018 - 2022
• 4.3 Product Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by End-user

• 6.1 Market segments
• 6.2 Comparison by End-user
• 6.3 Hospitals - Market size and forecast 2023-2028
• 6.4 Research institutes - Market size and forecast 2023-2028
• 6.5 Biotechnology companies - Market size and forecast 2023-2028
• 6.6 Others - Market size and forecast 2023-2028
• 6.7 Market opportunity by End-user

7 Market Segmentation by Product

• 7.1 Market segments
• 7.2 Comparison by Product
• 7.3 Consumable and kits - Market size and forecast 2023-2028
• 7.4 Instrument - Market size and forecast 2023-2028
• 7.5 Services and others - Market size and forecast 2023-2028
• 7.6 Market opportunity by Product

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 China - Market size and forecast 2023-2028
• 9.9 UK - Market size and forecast 2023-2028
• 9.10 Germany - Market size and forecast 2023-2028
• 9.11 Canada - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 Allele Biotechnology and Pharmaceuticals Inc.
• 12.4 Applied Biological Materials Inc.
• 12.5 Applied StemCell
• 12.6 ATCC
• 12.7 Axol Biosciences Ltd.
• 12.8 Cynata Therapeutics Ltd.
• 12.9 Evotec SE
• 12.10 Fate Therapeutics Inc.
• 12.11 FUJIFILM Corp.
• 12.12 Hitachi Ltd.
• 12.13 LIFE and BRAIN GmbH
• 12.14 Lonza Group Ltd.
• 12.15 Ncardia Services B.V.
• 12.16 REPROCELL Inc.
• 12.17 Takara Bio Inc.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations